Identification of MRI and 1H MRSI parameters that may predict survival for patients with malignant gliomas

NMR in Biomedicine

Volumn 17, Issue 1, 2004, Pages 10-20

  Li, Xiaojuan ^a   Jin, Hua ^a,c   Lu, Ying ^a,b   Oh, Joonmi ^a   Chang, Susan ^a   Nelson, Sarah J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SOUTH CHINA NORMAL UNIVERSITY   (China)

Author keywords

Brain tumors; Magnetic resonance imaging; Magnetic resonance spectroscopic imaging; Recursive partitioning; Tree structured survival analysis

Indexed keywords

BRAIN; HEALTH RISKS; NUCLEAR MAGNETIC RESONANCE; PATIENT TREATMENT; TUMORS;

BRAIN TUMORS; HISTOLOGICAL GRADES;

BIOMEDICAL ENGINEERING;

CHOLINE; CREATININE; LACTIC ACID; LIPID; N ACETYLASPARTIC ACID; PROTON;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; GLIOBLASTOMA; GROUPS BY AGE; HISTOPATHOLOGY; HUMAN; KAPLAN MEIER METHOD; MALE; MEDICAL PARAMETERS; MULTIMODALITY CANCER THERAPY; PLOTS AND CURVES; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE EVALUATION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTON NUCLEAR MAGNETIC RESONANCE; SIGNAL DETECTION; SURVIVAL TIME; THREE DIMENSIONAL IMAGING; BRAIN TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED DIAGNOSIS; GLIOMA; METHODOLOGY; MIDDLE AGED; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SURVIVAL; TREATMENT OUTCOME; UNITED STATES; VALIDATION STUDY;

ADULT; AGED; BRAIN NEOPLASMS; FEMALE; GLIOMA; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PROGNOSIS; PROTONS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 1542516145     PISSN: 09523480     EISSN: None     Source Type: Journal    
DOI: 10.1002/nbm.858     Document Type: Article

References (47)

1. Sneed PK, Prados MD, McDermott MW, Larson DA, Malec MK, Lamborn KR, Davis RL, Weaver KA, Wara WM, Phillips TL, Gutin PH. Large effect of age on the survival of patients with glioblastoma treated with radiotherapy and brachytherapy boost. Neurosurgery 1995; 36: 898-903; discussion 903-904.
2. Scott CB, Scarantino C, Urtasun P, Movsas B, Jones CU, Simpson JR, Fischbach JA, Curran WJ Jr. Validation and predictive power of radiation therapy oncology group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int. J. Radiat. Oncol. Biol. Phys. 1998; 40: 51-55.
3. Davis FG, McCarthy BJ, Freels S, Kupelian V, Bondy ML. The conditional probability of survival of patients with primary malignant brain tumors: surveillance, epidemiology, and end results (SEER) data. Cancer 1999; 85: 485-491.
4. Negendank WG, Sauter R, Brown TR. Proton magnetic resonance spectroscopy in patients with glial tumors: a multicenter trial. J. Neurosurg. 1996; 84: 449-458.
5. Vigneron DB, Bollen A, McDermott M, Wald L, Day M, Moyher-Noworolski S, Henry R, Chang S, Berger M, Dillon W, Nelson SJ. Three-dimensional magnetic resonance spectroscopic imaging of histologically confirmed brain tumors. Magn. Reson. Imag. 2001; 19: 89-101.
6. Rock JP, Hearshen D, Scarpace L, Croteau D, Gutierrez J, Fisher JL, Rosenblum ML, Mikkelsen T. Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis. Neurosurgery 2002; 51: 912-919.
7. Lee PL, Gonzalez RG. Magnetic resonance spectroscopy of brain tumors. Curr. Opin. Oncol. 2000; 12: 199-204.
8. 1H-MRS) in the diagnosis and management of patients with brain tumors. Curr. Opin. Oncol. 2002; 14: 292-298.
9. Segal MR. Regression trees for censored data. Biometrics 1988. 44: 35-47.
10. Therneau T, Grambsch P, Fleming T. Martingale based residuals for survival models. Biometrika 1990; 77: 147-160.
11. Zhang H, Singer D. Recursive Partitioning Tree and Application in Health Sciences. Springe: New York, 1999.
12. Li X, Lu Y, Nelson SJ. Gliomas classification by recursive partitioning tree and discriminant analysis using in vivo MRI/MRSI data. 2002 IEEE International Symposium on Biomedical Imaging 2002.
13. Li X, Lu Y, Pirzkall A, McKnight TR, Nelson SJ. Analysis of the spatial characteristics of metabolic abnormalities in newly diagnosed glioma patients. J. Magn. Reson. Imag. 2002; 16: 229-237.
14. Star-Lack J, Vigneron DB, Pauly J, Kurhanewicz J, Nelson SJ. Improved solvent suppression and increased spatial excitation bandwidths for three-dimensional PRESS CSI using phase-compensating spectral/spatial spin-echo pulses. J. Magn. Reson. Imag. 1997; 7: 745-757.
15. Tran TK, Vigneron DB, Sailasuta N, Tropp J, Le Roux P, Kurhanewicz J, Nelson S, Hurd R. Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer. Magn. Reson. Med. 2000; 43: 23-33.
16. Nelson SJ. Analysis of volume MRI and MR spectroscopic imaging data for the evaluation of patients with brain tumors. Magn. Reson. Med. 2001; 46: 228-239.
17. McKnight TR, Noworoski SM, Vigneron DB, Nelson SJ. An automated technique for the quantitative assessment of 3D-MRSI data from patients with glioma. J. Magn. Reson. Imag. 2001; 13: 167-177.
18. McKnight TR, von dem Bussche MH, Vigneron DB, Lu Y, Berger MS, McDermott MW, Dillon WP, Graves EE, Pirzkall A, Nelson SJ. Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J. Neurosurg. 2002; 97: 794-802.
19. Morgan J, Sonquist J. Problems in the analysis of survey data and a proposal. J. Am. Stat. Assoc. 1963; 58: 415-434.
20. Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and Regression Trees. Wadsworth: Belmont, 1984.
21. Kaibara T, Tyson RL, Sutherland GR. Human cerebral neoplasms studied using MR spectroscopy: a review. Biochem. Cell Biol. 1998; 76: 477-486.
22. Cheng LL, Chang I-W, Louis DN, Gonzalez RG. Correlation of high-resolution magic angle spinning proton magnetic resonance spectroscopy with histopathology of intact human brain tumor specimens. Cancer Res. 1998; 58(9): 1825-1832.
23. Shimizu H, Kumabe T, Tominaga T, Kayama T, Hara K, Ono Y, Sato K, Arai N, Fujiwara S, Yoshimoto T. Noninvasive evaluation of malignancy of brain tumors with proton MR spectroscopy. AJNR Am. J. Neuroradiol. 1996; 17: 737-747.
24. Preul MC, Caramanos Z, Leblanc R, Villemure JG, Arnold DL. Using pattern analysis of in vivo proton MRSI data to improve the diagnosis and surgical management of patients with brain tumors. NMR Biomed. 1998; 11: 192-200.
25. Rutter A, Hugenholtz H, Saunders JK, Smith IC. Classification of brain tumors by ex vivo 1H NMR spectroscopy. J. Neurochem. 1995; 64: 1655-1661.
26. 1H MR spectra of human brain neoplasms: the influence of preprocessing and computerized consensus diagnosis on classification accuracy. J. Magn. Reson. Imag. 1996; 6: 437-444.
27. Pirzkall A, McKnight TR, Graves EE, Carol MP, Sneed PK, Wara WW, Nelson SJ, Verhey LJ, Larson DA. MR-spectroscopy guided target delineation for high-grade gliomas. Int. J. Radiat. Oncol. Biol. Phys. 2001; 50: 915-928.
28. Walliann T, Wyss M, Brdiczka D, Nicolay K, Eppenberger HM. Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the 'phosphocreatine circuit' for cellular energy homeostasis. Biochem. J. 1992; 281: 21-40.
29. 1H NMR spectroscopy in vivo and in vitro. Neurochemistry 1994; 63: 1538-1543.
30. 1H magnetic resonance spectroscopy and in vitro analyses of heterogeneous brain tumors. J. Neuroimaging. 1995; 5: 157-163.
31. 1H NMR spectroscopy studies of extracts of human cerebral neoplasms. Magn. Reson. Imag. 1992; 24: 123-136.
32. Alger JR, Frank JA, Bizzi A, Fulham MJ, DeSouza BX, Duhaney MO, Inscoe SW, Black JL, van Zijl PCM, Moonen CTW, Di Chiro G. Metabolism of human gliomas: Assessment with H-1 MR spectroscopy and F-18 flourodeoxyglucose PET. Radiology 1990; 177: 633-641.
33. Tzika AA, Zurakowski D, Poussaint TY, Goumnerova L, Astrakas LG, Barnes PD, Anthony DC, Billett AL, Tarbell NJ, Scott RM, Black PM. Proton magnetic spectroscopic imaging of the child's brain: the response of tumors to treatment. Neuroradiology 2001; 43: 169-177.
34. 1H nuclear magnetic resonance correspond to lipid droplets. Cancer Res. 1997; 57(3): 407-414.
35. 1H MRS of high grade astrocytomas: mobile lipid accumulation in necrotic tissue. NMR Biomed. 1994; 7: 149-155.
36. Kaminogo M, Ishimaru H, Morikawa M, Ochi M, Ushijima R, Tani M, Matsuo Y, Kawakubo J, Shibata S. Diagnostic potential of short echo time MR spectroscopy of gliomas with single-voxel and point-resolved spatially localized proton spectroscopy of brain. Neuroradiology 2001; 43: 353-363.
37. Warburg O. The Metabolism of Tumors. Constable: New York, 1930.
38. Prichard JW. What the clinician can learn from MRS lactate measurement. NMR Biomed 1991; 4: 99-102.
39. Go KG, Kamman RL, Mooyaart EL, Heesters MA, Pruim J, Vaalburg W, Paans AM. Localized proton spectroscopy and spectroscopic imaging in cerebral gliomas, with comparison to positron emission tomography. Neuroradiology 1995; 37: 198-206.
40. Tien RD, Lai PH, Smith JS, Lazeyras F. Single-voxel proton brain spectroscopy exam (PROBE/SV) in patients with primary brain tumors. AJNR Am. J. Neuroradiol. 1996; 167: 201-209.
41. Falini A, Calabrese G, Origgi D. Proton magnetic resonance spectroscopy and intracranial tumors: clinical perspective. J. Neurol. 1996; 243: 706-714.
42. Stone HB, Brown JM, Phillips TL, Sutherland RM. Oxygen in human tumors: correlations between methods of measurement and response to therapy. Summary of a workshop held November 19-20, 1992, at the National Cancer Institute, Bethesda, Maryland. Radiat. Res. 1993; 136: 422-434.
43. Aboagye EO, Kelson AB, Tracy M, Workman P. Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography. Anticancer Drug Des. 1998; 13: 703-730.
44. 1H-MRS in vivo predicts the early treatment outcome of postoperative radiotherapy for malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys. 2002; 52: 1271-1276.
45. Walenta S, Schroeder T, Mueller-Klieser W. Metabolic mapping with bioluminescence: basic and clinical relevance. Biomol. Eng. 2002; 18: 249-262.
46. LeBlanc M, Crowley J. Relative risk trees for censored survival data. Biometrics 1992; 48: 411-425.
47. Keles S, Segal MR. Residual-based tree-structured survival analysis. Stat. Med. 2002; 21: 313-326.